Search results for: INVERSE AGONIST

• INVERSE PROBLEMS

  Journals

  ISSN: 0266-5611 , eISSN: 1361-6420

• Inverse Problems and Imaging

  Journals

  ISSN: 1930-8337 , eISSN: 1930-8345

• The Monist

  Journals

  ISSN: 0026-9662 , eISSN: 2153-3601

• Protecting Wireless Mesh Networks Against Adverse Weather Conditions

  Publication

  • E. Fitzgerald
  • M. Pioro
  • A. Tomaszewski

  - Year 2018

  Full text to download in external service

• Inverse shadowing and related measures

  Publication

  • S. Kryzhevich
  • S. Pilyugin

  - Science China-Mathematics - Year 2020

  We study various weaker forms of the inverse shadowing property for discrete dynamical systems on a smooth compact manifold. First, we introduce the so-called ergodic inverse shadowing property (Birkhoff averages of continuous functions along an exact trajectory and the approximating one are close). We demonstrate that this property implies the continuity of the set of invariant measures in the Hausdorff metric. We show that the...

  Full text available to download

• INVERSE PROBLEMS IN SCIENCE AND ENGINEERING

  Journals

  ISSN: 1741-5977 , eISSN: 1741-5985

• Inverse Potassium Hydride:  A Theoretical Study

  Publication

  • A. Sawicka
  • P. Skurski
  • J. Simons

  - JOURNAL OF PHYSICAL CHEMISTRY A - Year 2005

  Full text to download in external service

• Inverse Sodium Hydride:  A Theoretical Study

  Publication

  • A. Sawicka
  • P. Skurski
  • J. Simons

  - JOURNAL OF THE AMERICAN CHEMICAL SOCIETY - Year 2003

  Full text to download in external service

• (4-(Bis(4-Fluorophenyl)Methyl)Piperazin-1-yl)(Cyclohexyl)Methanone Hydrochloride (LDK1229): A New Cannabinoid CB1 Receptor Inverse Agonist from the Class of Benzhydryl Piperazine Analogs

  Publication

  • M. M. Mahmoud
  • T. Olszewska
  • H. Liu
  • D. M. Shore
  • D. P. Hurst
  • P. H. Reggio
  • D. Lu
  • D. A. Kendall

  - MOLECULAR PHARMACOLOGY - Year 2015

  Some inverse agonists of cannabinoid receptor type 1 (CB1) have been demonstrated to be anorectic antiobesity drug candidates. However, the first generation of CB1 inverse agonists, represented by rimonabant (SR141716A), otenabant, and taranabant, are centrally active, with a high level of psychiatric side effects. Hence, the discovery of CB1 inverse agonists with a chemical scaffold distinct from these holds promise for developing...

  Full text to download in external service

• Universe-Taipei

  Journals

  ISSN: 2309-852X